CircGPC3 promotes hepatocellular carcinoma progression and metastasis by sponging miR-578 and regulating RAB7A/PSME3 expression.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Carcinoma, Hepatocellular*/pathology ; Liver Neoplasms*/pathology ; MicroRNAs*/genetics ; MicroRNAs*/metabolism ; RNA, Long Noncoding*/metabolism; Humans ; RNA, Circular/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; Cell Movement/genetics

CircRNAs are a class of highly stable noncoding RNAs that play an important role in the progression of many diseases, especially cancer. In this study, high-throughput sequencing was used to screen for abnormally expressed circRNAs, and we found that circGPC3 was overexpressed in HCC tissues. However, the underlying mechanism of circGPC3 in the development and metastasis of hepatocellular carcinoma (HCC) remains unknown. In our study, we found that circGPC3 was significantly upregulated in HCC tissues and cells and that its overexpression was positively correlated with overall survival, TNM stage and lymph node metastasis. In vivo and in vitro experiments showed that circGPC3 knockdown repressed HCC cell migration, invasion and proliferation and promoted apoptosis. Mechanistically, circGPC3 promoted HCC proliferation and metastasis through the miR-578/RAB7A/PSME3 axis. Our results demonstrate that circGPC3 contributes to the progression of HCC and provides an intervention target for HCC.
(© 2024. The Author(s).)

Oncoimmunology. 2020 May 21;9(1):1761205. (PMID: 32923122)
Cancer Cell Int. 2020 Aug 18;20:400. (PMID: 32831653)
Cell Death Dis. 2020 Jan 6;11(1):18. (PMID: 31907361)
Signal Transduct Target Ther. 2022 Apr 13;7(1):121. (PMID: 35418578)
Mol Cancer. 2019 Jun 1;18(1):105. (PMID: 31153371)
Mol Cancer. 2020 Feb 15;19(1):30. (PMID: 32059672)
Cell Signal. 2023 Nov;111:110858. (PMID: 37633479)
J Transl Med. 2018 Aug 9;16(1):220. (PMID: 30092792)
Int J Mol Sci. 2020 Sep 23;21(19):. (PMID: 32977537)
Cell Death Differ. 2022 Mar;29(3):481-491. (PMID: 35169296)
Brief Bioinform. 2021 Mar 22;22(2):1706-1728. (PMID: 32103237)
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224)
Cells. 2022 Nov 11;11(22):. (PMID: 36429000)
Mol Cancer. 2022 Jul 20;21(1):149. (PMID: 35858900)
Trends Cancer. 2020 Apr;6(4):319-336. (PMID: 32209446)
Thorac Cancer. 2023 Sep;14(26):2665-2677. (PMID: 37533139)
Gastroenterology. 2021 Jun;160(7):2572-2584. (PMID: 33705745)
Comput Struct Biotechnol J. 2021 Jan 22;19:910-928. (PMID: 33598105)
Cancer Lett. 2017 Feb 1;386:161-167. (PMID: 27756569)
Mol Ther. 2020 Jun 3;28(6):1506-1517. (PMID: 32304667)
Sci Adv. 2018 Nov 21;4(11):eaav0443. (PMID: 30627666)
Thorac Cancer. 2021 Aug;12(16):2258-2264. (PMID: 34236145)
Nat Rev Gastroenterol Hepatol. 2023 Apr;20(4):203-222. (PMID: 36369487)
Exp Cell Res. 2017 Sep 15;358(2):87-93. (PMID: 28529105)
Am J Cancer Res. 2023 Jun 15;13(6):2360-2375. (PMID: 37424831)
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2597-2605.e4. (PMID: 32889146)
Cells. 2019 Mar 08;8(3):. (PMID: 30857122)
Mol Cancer. 2020 Dec 14;19(1):172. (PMID: 33317550)
Front Oncol. 2020 Aug 19;10:1388. (PMID: 32974140)
Ann Hepatol. 2022 Mar-Apr;27(2):100678. (PMID: 35093599)
J Orthop Surg Res. 2021 May 7;16(1):300. (PMID: 33962616)
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. (PMID: 31439937)
Front Pharmacol. 2021 May 13;12:657053. (PMID: 34054537)
Clin Breast Cancer. 2023 Apr;23(3):281-290. (PMID: 36628810)
Cancers (Basel). 2021 May 06;13(9):. (PMID: 34066419)
J Exp Clin Cancer Res. 2022 Jul 11;41(1):218. (PMID: 35821160)
Circulation. 2020 Aug 11;142(6):556-574. (PMID: 32441115)
Genes Dis. 2020 Jan 27;7(3):308-319. (PMID: 32884985)
Nat Rev Genet. 2019 Nov;20(11):675-691. (PMID: 31395983)
Cancers (Basel). 2021 Jun 02;13(11):. (PMID: 34199580)
Hepatology. 2020 Sep;72(3):906-922. (PMID: 31838741)
Mol Cancer. 2022 Mar 11;21(1):72. (PMID: 35277182)
Signal Transduct Target Ther. 2020 Jun 10;5(1):87. (PMID: 32532960)
Nat Rev Clin Oncol. 2022 Mar;19(3):188-206. (PMID: 34912049)

JCZ2022036 the Nantong Science and Technology Bureau; JCZ2022080 the Nantong Science and Technology Bureau; Z2020011 the Health Commission of Jiangsu Province; LKM2023041 the Health Commission of Jiangsu Province; QA20210039 the Nantong Municipal Health Commission; QN2022041 the Nantong Municipal Health Commission

0 (MicroRNAs)
0 (RNA, Circular)
0 (RNA, Long Noncoding)

Date Created: 20240401 Date Completed: 20240403 Latest Revision: 20240404

20240404

PMC10984923

10.1038/s41598-024-58004-y

38561366